![Paul Clancy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Clancy
Presidente presso XILIO THERAPEUTICS, INC.
Patrimonio netto: 2 M $ in data 31/05/2024
Profilo
Mr. Paul J.
Clancy is an Independent Chairman at Sionna Therapeutics, Inc., an Independent Director at EXACT Sciences Corp., a Chairman at Xilio Therapeutics, Inc., an Independent Director at Incyte Corp.
and a Secretary, Director & Vice President at Stromedix, Inc. He is on the Board of Directors at EXACT Sciences Corp., Incyte Corp.
and Stromedix, Inc. Mr. Clancy was previously employed as a Chief Financial Officer & Executive Vice President by Alexion Pharmaceuticals, Inc., an Independent Director by Agios Pharmaceuticals, Inc., a Chief Financial Officer & Executive Vice President by Biogen Idec New Ventures, Inc., a Chief Financial Officer & EVP-Finance by Biogen, Inc., a Senior Vice President-Finance by Biogen Idec, Inc. (North Carolina), a President & Director by Bioverativ Therapeutics, Inc., and a VP & General Manager-Great West Business Unit by PepsiCo, Inc. He received his undergraduate degree from Babson College and an MBA from Columbia Business School.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
INCYTE CORPORATION
0.01% | 28/06/2024 | 19 014 ( 0.01% ) | 1 M $ | 31/05/2024 |
13/06/2024 | 20 145 ( 0.01% ) | 915 590 $ | 31/05/2024 | |
XILIO THERAPEUTICS INC
-.--% | 14/06/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Posizioni attive di Paul Clancy
Società | Posizione | Inizio |
---|---|---|
INCYTE CORPORATION | Direttore/Membro del Consiglio | 20/01/2015 |
XILIO THERAPEUTICS, INC. | Presidente | 16/06/2022 |
EXACT SCIENCES CORPORATION | Direttore/Membro del Consiglio | 18/03/2021 |
Stromedix, Inc.
![]() Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | - |
Sionna Therapeutics, Inc.
![]() Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Presidente | 06/06/2022 |
Precedenti posizioni note di Paul Clancy
Società | Posizione | Fine |
---|---|---|
AGIOS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 13/06/2023 |
ALEXION PHARMACEUTICALS, INC. | Direttore Finanziario/CFO | 01/11/2019 |
BIOGEN INC. | Direttore Finanziario/CFO | 13/06/2017 |
Biogen Idec, Inc. (North Carolina)
![]() Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Direttore Finanziario/CFO | 13/06/2017 |
░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░ | - |
Formazione di Paul Clancy
Babson College | Undergraduate Degree |
Columbia Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 6 |
---|---|
BIOGEN INC. | Health Technology |
PEPSICO, INC. | Consumer Non-Durables |
AGIOS PHARMACEUTICALS, INC. | Health Technology |
INCYTE CORPORATION | Health Technology |
XILIO THERAPEUTICS, INC. | Health Technology |
EXACT SCIENCES CORPORATION | Health Technology |
Aziende private | 6 |
---|---|
Biogen Idec New Ventures, Inc.
![]() Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | Finance |
Biogen Idec, Inc. (North Carolina)
![]() Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Bioverativ Therapeutics, Inc.
![]() Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. | Health Technology |
Stromedix, Inc.
![]() Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Sionna Therapeutics, Inc.
![]() Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | Health Services |
- Borsa valori
- Insiders
- Paul Clancy